Companies · Biotechnology

Solidagex, Inc.

LOUISVILLE · Biotechnology

Diligence memoA one-page analyst read on Solidagex, Inc. — recommendation, valuation, rhythm, risks.
$315K
Total raised · real
2
Rounds
2.1×
Latest step-up
Top 94%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Jan 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Solidagex, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.75× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
  • Within the normal band (75% of peer median) for its niche.
Dormant
  • Last raise 12.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Solidagex, Inc. is one of 4291 Biotechnology companies tracked from LOUISVILLE. By capital raised it ranks in the long tail (ahead of 7% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2012-01-06 Raised $100K (real) Modeled valuation $5.5M (est)$100K$5.5MPre-Seed2012Pre-Seed · 2014-01-02 Raised $215K (real) Modeled valuation $12M (est)$215K$12MPre-Seed2014+$215KCumulative $315K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2012
Pre-Seed extension$215K · 2014

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$11.9M
Base estimate est.
$115K
Conservative case
$134.6M
Upside case
$1.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $5.5M · 2012-01-062012Pre-Seed · modeled $11.9M · 2014-01-022014
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
12.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
24 mo
Avg between rounds
$158K/yr
Capital velocity
14.5 yr
On record since
2012
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$315K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.5× of median
This company$215K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$11.9M
Sector median$64.2M

Raised more than 7% of sector peers (real $). Modeled value above 21% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #88 of 131.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Truminim, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Direct Spinal Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Imanis Life Sciences, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Universal Biosensors Inc · Pre-Seed Raised $985K · modeled $54.4M (est)One World Lab, Inc. · Pre-Seed Raised $981K · modeled $54.2M (est)Micropharma Ltd · Pre-Seed Raised $851K · modeled $47.0M (est)ConverGene LLC · Pre-Seed Raised $850K · modeled $46.9M (est)CVUS Ventures, LP · Pre-Seed Raised $850K · modeled $46.9M (est)Symbiotic Health, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)EternoGen Aesthetics, LLC · Pre-Seed Raised $939K · modeled $46.3M (est)Genomics USA, Inc. · Pre-Seed Raised $837K · modeled $46.2M (est)Immunetics, Inc. · Pre-Seed Raised $1.5M · modeled $46.1M (est)Solidagex, Inc. (this company) Raised $315K · modeled $11.9M (est)Solidagex, Inc.
CompanyStageRaised · realValue · estvs peer med.
Truminim, LLCPre-Seed$1.0M$55.2M3.48×
Direct Spinal Therapeutics, Inc.Pre-Seed$1.0M$55.2M3.48×
Imanis Life Sciences, LLCPre-Seed$1.0M$55.2M3.48×
Universal Biosensors IncPre-Seed$985K$54.4M3.43×
One World Lab, Inc.Pre-Seed$981K$54.2M3.42×
Micropharma LtdPre-Seed$851K$47.0M2.96×
ConverGene LLCPre-Seed$850K$46.9M2.96×
CVUS Ventures, LPPre-Seed$850K$46.9M2.96×
Symbiotic Health, Inc.Pre-Seed$850K$46.9M2.96×
EternoGen Aesthetics, LLCPre-Seed$939K$46.3M2.92×
Genomics USA, Inc.Pre-Seed$837K$46.2M2.92×
Immunetics, Inc.Pre-Seed$1.5M$46.1M2.91×
Solidagex, Inc. this companyPre-Seed$315K$11.9M0.75×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2012-01-06$556K$5.5M90%
Pre-Seed$215K2014-01-02$1.2M$11.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2012-01-06
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$215K2014-01-02
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
Intelligence
2015 ~Q4
Modeled next raise · ~24mo cadence
$462K
Modeled next size est.range $300K$740K
2.1×
Last step-up
$158K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ben K Self2014-01
David K McClure2014-01
John M Littleton2012-01
Ted K Steinbock2014-01
Terry K Minton2012-01
Tony K Schy2014-01
Registry & provenance

Solidagex, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1541591
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Persephone Biosciences, Inc.BiotechnologyPre-Seed$317K$11.8Msame sector · same stage
Acomhal Research, Inc.BiotechnologyPre-Seed$300K$10.2Msame sector · same stage
Biomedica Management CorpBiotechnologyPre-Seed$300K$11.0Msame sector · same stage
Ideal Medical Technologies Inc.BiotechnologyPre-Seed$300K$11.0Msame sector · same stage
Nexome Genomics Inc.BiotechnologyPre-Seed$300K$10.3Msame sector · same stage
bioVidria, Inc.BiotechnologyPre-Seed$350K$8.3Msame sector · same stage
PARTURA Medical, Inc.BiotechnologyPre-Seed$280K$15.5Msame sector · same stage
Ariste Medical, Inc.BiotechnologyPre-Seed$275K$15.2Msame sector · same stage
Frequently asked
How much funding has Solidagex, Inc. raised?
Solidagex, Inc. has raised approximately $315K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Solidagex, Inc.'s estimated valuation?
Provath's modeled valuation for Solidagex, Inc. is approximately $11.9M (modeled range $115K–$134.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Solidagex, Inc. at?
Solidagex, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Jan 02.
What does Solidagex, Inc. do and where is it based?
Solidagex, Inc. operates in the Biotechnology sector, based in LOUISVILLE.
Explore related

See where Solidagex, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Solidagex, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.